Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
WC Kwok, JCM Ho, TCC Tam, MSM Ip… - Thoracic …, 2022 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting
WC Kwok, JCM Ho, TCC Tam, MSM Ip, DCL Lam - Thoracic Cancer, 2022 - hub.hku.hk
Background: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are
recommended as first-line treatment in non-small cell lung cancer (NSCLC) patients with …
recommended as first-line treatment in non-small cell lung cancer (NSCLC) patients with …
Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.
WC Kwok, JCM Ho, TCC Tam, MSM Ip, DCL Lam - Thoracic Cancer, 2022 - europepmc.org
Background Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are
recommended as first-line treatment in non-small cell lung cancer (NSCLC) patients with …
recommended as first-line treatment in non-small cell lung cancer (NSCLC) patients with …
Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
CK Wang, JCM Ho, TCC Tam, MSM Ip… - Thoracic …, 2022 - search.proquest.com
Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting
WC Kwok, JCM Ho, TCC Tam, MSM Ip… - Thoracic …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are
recommended as first-line treatment in non-small cell lung cancer (NSCLC) patients with …
recommended as first-line treatment in non-small cell lung cancer (NSCLC) patients with …
[HTML][HTML] Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
WC Kwok, JCM Ho, TCC Tam, MSM Ip… - Thoracic Cancer, 2022 - ncbi.nlm.nih.gov
Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.
WC Kwok, JCM Ho, TCC Tam, MSM Ip, DCL Lam - Thoracic Cancer, 2022 - europepmc.org
Background Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are
recommended as first-line treatment in non-small cell lung cancer (NSCLC) patients with …
recommended as first-line treatment in non-small cell lung cancer (NSCLC) patients with …
[引用][C] Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
WC Kwok, JCM Ho, CCT Tam, MSM Ip, CLD Lam - Thoracic Cancer, 2022 - hub.hku.hk
HKU Scholars Hub: Survival benefits from afatinib compared with gefitinib and erlotinib among
patients with common EGFR mutation in first‐line setting Skip navigation HKU Login Guest …
patients with common EGFR mutation in first‐line setting Skip navigation HKU Login Guest …